February 2022

Biohaven Licenses a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA)

Leave a Comment / Front Page News, Industry Updates, Research /

Biohaven Pharmaceutical Holding Company Ltd., announced today that it entered into a worldwide license agreement with Bristol Myers Squibb for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Taldefgrobep is the third development asset licensed to Biohaven from Bristol Myers Squibb and a clinical trial for SMA is expected to […]

Biohaven Licenses a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA) Read More »

International Day of Women and Girls in Science

Leave a Comment / Front Page News, Research, Support & Care /

Did you know? February 11 is International Day of Women and Girls in Science! While we’ve seen significant progress related to participation of women and girls in science, technology, engineering, and math (STEM), they are still underrepresented in these fields. For continued innovation and development in STEM, it’s imperative that women and girls feel empowered

International Day of Women and Girls in Science Read More »

Scroll to Top